January 5th 2018
By Brielle Benyon
NextSource Pharma, a small pharmaceutical company based in Florida, acquired the drug lomustine from Bristol-Myers Squibb, changed its brand name to Gleostine, and changed the price – by about 1,400 percent.
January 3rd 2018
By Bonnie Annis
Most Americans have insurance. We find comfort in knowing our future is secure in the event of a health crisis. But how do we know how much insurance is enough? Is it wise to take our specialized policies?
December 28th 2017
By Katie Kosko
Musella’s plan for the Brain Tumor Virtual Trial Registry is to get patients access to more drugs at a faster pace, while collecting treatment and efficacy information that can later be used by oncologists across the country to treat others.
December 25th 2017
Not all employees with cancer get paid leave, but those who did saw better health and financial outcomes.
December 21st 2017
By Debu Tripathy, M.D.
FINANCIAL TOXICITY IS AN increasingly used term that describes the multiple negative consequences of medical care costs on the patient, whether it be for cancer or another serious illness.
December 18th 2017
By Dellann Elliott Mydland
An easier application process could make experimental drugs more accessible to patients in need — outside the realm of clinical trials.
December 6th 2017
By Don Vaughan
Organizations offer free services and goods for patients with cancer.
December 3rd 2017
By Mark Cantrell
During his career doing humanitarian work in the Middle East and central Asia, Len Rodgers has been no stranger to adversity. In 1967, he and his family were evacuated from Lebanon during the Six-Day War. “I’ve seen just about every Middle East war since,” Rodgers says. But in 2003, he faced his biggest battle yet.
December 2nd 2017
By Marijke Vroomen Durning, RN
Hotel Keys of Hope offers patients discounted or free hotel rooms to ease travel for cancer care.
By CURE staff
Experts Urge Greater Awareness and Support as Liver Cancer Month Ends
Finding Humor in a Cancer Journey
Pancreatic Cancer on the Rise Among Younger Adults
Covering Every FDA Oncology Approval From October 2025